Products for Research Use Only
RegisterLogin

Evogliptin (tartrate)

CAT: 0804-HY-117985B-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-117985B-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Evogliptin (DA-1229) tartrate is an orally active DPP4 inhibitor with significant and sustained hypoglycaemic effects in mouse models. Evogliptin tartrate also inhibits the production of inflammatory and fibrotic signals in hepatocytes by inducing autophagy. Evogliptin tartrate can be used in studies of type 2 diabetes, osteoporosis, renal impairment and chronic liver inflammation[1][2][3][4].
CAS Number
1222102-51-3
Product Name Alternative
DA-1229 (tartrate)
UNSPSC
12352005
Target
Autophagy; Dipeptidyl Peptidase
Type
Reference compound
Related Pathways
Autophagy; Metabolic Enzyme/Protease
Applications
Metabolism-protein/nucleotide metabolism
Field of Research
Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/evogliptin-tartrate.html
Purity
99.71
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
O=C1NCCN(C(C[C@H](N)CC2=CC(F)=C(F)C=C2F)=O)[C@@H]1COC(C)(C)C.O=C(O)[C@H](O)[C@@H](O)C(O)=O
Molecular Formula
C23H32F3N3O9
Molecular Weight
551.51
References & Citations
[1]Yoon H, et al. Effects of the Antidiabetic Drugs Evogliptin and Sitagliptin on the Immune Function of CD26/DPP4 in Th1 Cells. Biomol Ther (Seoul) . 2021 Mar 1;29 (2) :154-165. |[2]Seo H Y, et al. Evogliptin Directly Inhibits Inflammatory and Fibrotic Signaling in Isolated Liver Cells. International Journal of Molecular Sciences, 2022, 23 (19) : 11636. |[3]Kim TH, et al. Hepatic role in an early glucose-lowering effect by a novel dipeptidyl peptidase 4 inhibitor, evogliptin, in a rodent model of type 2 diabetes. Eur J Pharmacol. 2016 Jan 15;771:65-76. |[4]Tan X, et al. Evogliptin: a new dipeptidyl peptidase inhibitor for the treatment of type 2 diabetes. Expert Opin Pharmacother. 2016 Jun;17 (9) :1285-93.
Shipping Conditions
Room Temperature
Storage Conditions
4°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 4
Isoform
DPP-4

Related Products

CatalogName
HY-117985Evogliptin
HY-117985SEvogliptin-d9
HY-117985AEvogliptin (hydrochloride)
HY-14834A-01Budiodarone (tartrate)
HY-14829BAfegostat (tartrate)
HY-105182A-01Xanomeline (tartrate)
HY-139347A-01Mazisotine (tartrate)
HY-B0519-01Tylosin (tartrate)
HY-10021-01Varenicline (Tartrate)
HY-129783Phenindamine (tartrate)

Alternative Products

CatalogName
FE182609-01Evogliptin tartrate
AR-E10891-01Evogliptin-d4 Tartrate
AR-E02259-01Evogliptin Tartrate Impurity S1
AR-E10890-01Evogliptin Tartrate Impurity S3
AR-E10889-01Evogliptin Tartrate Impurity S2
AR-E08836-013-Ethylamino Evogliptin Tartrate
TRC-D459015-100MG3,4-Difluorophenyl Evogliptin Tartrate
AR-E08834-012,5-Difluorophenyl Evogliptin Tartrate
TRC-E945900-75MGent-Evogliptin L-Tartrate Salt
TRC-E945905-50MG(3'S)-Evogliptin L-tartrate Salt

Popular Products